NASDAQ · NVCR
Healthcare · Medical - Instruments & Supplies
$13.43
Up+$1.18 (+8.79%)
Updated Nov 4, 2026, 10:07 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NVCR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
NVCR closed at $13.43 after 21 trading sessions, down 10.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $13.30 | $13.555 | $13.21 | $13.43 | 1.65M |
| Nov 2, 2026 | $13.33 | $13.67 | $13.08 | $13.21 | 1.65M |
| Oct 30, 2026 | $12.81 | $13.26 | $12.515 | $13.15 | 1.97M |
| Oct 29, 2026 | $12.605 | $13.85 | $11.85 | $13.11 | 5.96M |
| Oct 28, 2026 | $14.44 | $14.64 | $13.845 | $14.17 | 2.39M |
| Oct 27, 2026 | $14.49 | $14.74 | $14.11 | $14.62 | 2.47M |
| Oct 26, 2026 | $14.47 | $14.895 | $14.20 | $14.40 | 1.17M |
| Oct 23, 2026 | $14.85 | $14.97 | $14.53 | $14.68 | 1.13M |
| Oct 22, 2026 | $15.55 | $15.655 | $14.935 | $15.10 | 1.06M |
| Oct 21, 2026 | $15.60 | $16.0942 | $15.43 | $15.59 | 2.6M |
| Oct 20, 2026 | $14.98 | $15.82 | $14.905 | $15.71 | 1.74M |
| Oct 19, 2026 | $14.14 | $15.00 | $14.14 | $14.89 | 2.23M |
| Oct 16, 2026 | $14.41 | $14.41 | $13.875 | $14.07 | 1.29M |
| Oct 15, 2026 | $13.85 | $14.46 | $13.835 | $14.41 | 1.81M |
| Oct 14, 2026 | $14.15 | $14.26 | $13.76 | $13.84 | 1.19M |
| Oct 13, 2026 | $14.66 | $14.75 | $14.29 | $14.30 | 772.63K |
| Oct 12, 2026 | $14.54 | $14.76 | $14.26 | $14.72 | 781.98K |
| Oct 9, 2026 | $14.17 | $14.78 | $14.14 | $14.58 | 1.02M |
| Oct 8, 2026 | $14.59 | $14.59 | $13.8207 | $14.22 | 2.96M |
| Oct 7, 2026 | $14.84 | $15.12 | $14.59 | $14.66 | 3.51M |
| Oct 6, 2026 | $15.27 | $15.88 | $14.90 | $14.97 | 1.76M |
The latest Smart Investors Daily articles mentioning NVCR.
Company
Market Activity
Research & News
NVCR research
Company profile and research snapshot.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Evercore ISI Group | Outperform | — |
| Oct 30, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 24, 2026 | Wedbush | Neutral | — |
| Jul 23, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
Generated Nov 4, 2026, 7:05 PM
NovoCure Limited shares surged 11.06% today, climbing $1.49 as investors reassess the company's long-term growth potential and international expansion strategy. Recent analyst commentary highlighting key investment takeaways and international revenue trends appears to be driving renewed interest in the oncology-focused medical device company.
Bottom line: NovoCure's 11% gain reflects renewed investor confidence in its international growth strategy and long-term value proposition as a specialized oncology player. While the stock's momentum is positive, investors should focus on tracking quarterly international revenue growth, reimbursement progress, and clinical trial outcomes rather than chasing short-term price movements.
Yahoo · Nov 2, 2026
Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Yahoo · Nov 2, 2026
Japan's emergence as a second major market is offsetting headwinds in pancreatic cancer, testing whether geographic diversification can sustain growth.
SeekingAlpha · Oct 31, 2026
2026-10-31. The following slide deck was published by NovoCure Limited in conjunction with their 2026 Q3 earnings call.
Yahoo · Oct 31, 2026
NovoCure came into this Q3 2026 report with a bruised chart, down double digits over the past month, yet the stock barely moved today, up just 0.3% around US$13. That muted reaction sits awkwardly against a quarter that delivered record net revenue of US$193.4m and the strongest profitability profile NovoCure has shown in recent periods, with adjusted EBITDA swinging into positive territory. Right now the market is treating this as a non-event. The numbers suggest a sentiment mismatch built...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVCR.
